Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FDMT NASDAQ:GHRS NASDAQ:IMNM NASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFDMT4D Molecular Therapeutics$4.29+3.2%$3.89$2.24▼$28.93$201.07M2.81801,510 shs37,141 shsGHRSGH Research$16.43+2.8%$12.58$6.00▼$20.50$854.85M0.96198,796 shs13,290 shsIMNMImmunome$9.13+8.7%$8.67$5.15▼$16.81$793.88M1.92901,183 shs395,364 shsSNDXSyndax Pharmaceuticals$9.34+1.4%$9.95$8.58▼$25.07$803.28M0.71.86 million shs175,605 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFDMT4D Molecular Therapeutics-5.02%-1.42%-5.24%+42.96%-84.55%GHRSGH Research-3.03%+10.50%+25.31%+83.79%+37.14%IMNMImmunome-1.29%-1.75%-8.70%+17.15%-40.68%SNDXSyndax Pharmaceuticals-6.50%+5.26%-10.15%-16.65%-62.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFDMT4D Molecular Therapeutics2.3651 of 5 stars3.33.00.00.01.91.70.6GHRSGH Research1.4992 of 5 stars3.51.00.00.02.40.80.0IMNMImmunome1.9992 of 5 stars3.50.00.00.03.62.50.0SNDXSyndax Pharmaceuticals3.0714 of 5 stars3.50.00.04.42.50.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFDMT4D Molecular Therapeutics 2.60Moderate Buy$29.56610.47% UpsideGHRSGH Research 3.00Buy$32.00100.13% UpsideIMNMImmunome 3.00Buy$23.33177.78% UpsideSNDXSyndax Pharmaceuticals 2.90Moderate Buy$34.10270.25% UpsideCurrent Analyst Ratings BreakdownLatest FDMT, GHRS, SNDX, and IMNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025SNDXSyndax PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$37.00 ➝ $35.007/12/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)7/10/2025SNDXSyndax PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.007/3/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/27/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (E+)6/24/2025GHRSGH ResearchJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$39.006/11/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)6/4/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.005/24/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/13/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.00 ➝ $21.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFDMT4D Molecular Therapeutics$40K4,818.32N/AN/A$11.05 per share0.38GHRSGH ResearchN/AN/AN/AN/A$3.44 per shareN/AIMNMImmunome$9.04M80.85N/AN/A$2.27 per share3.70SNDXSyndax Pharmaceuticals$23.68M33.47N/AN/A$3.38 per share2.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFDMT4D Molecular Therapeutics-$160.87M-$3.18N/AN/AN/A-767,126.06%-33.26%-30.68%8/6/2025 (Estimated)GHRSGH Research-$38.96M-$0.79N/AN/AN/AN/A-19.20%-18.40%9/2/2025 (Estimated)IMNMImmunome-$292.96M-$3.18N/AN/AN/A-1,875.21%-71.65%-60.36%8/11/2025 (Estimated)SNDXSyndax Pharmaceuticals-$318.76M-$3.86N/AN/AN/A-757.53%-101.60%-58.41%8/7/2025 (Estimated)Latest FDMT, GHRS, SNDX, and IMNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025IMNMImmunome-$0.52N/AN/AN/A$1.03 millionN/A8/7/2025Q2 2025SNDXSyndax Pharmaceuticals-$0.99N/AN/AN/AN/AN/A8/6/2025Q2 2025FDMT4D Molecular Therapeutics-$0.6922N/AN/AN/A$0.52 millionN/A5/12/2025Q1 2025IMNMImmunome-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million5/8/2025Q1 2025FDMT4D Molecular Therapeutics-$0.84-$0.86-$0.02-$0.86$0.53 millionN/A5/8/2025Q1 2025GHRSGH Research-$0.61-$0.19+$0.42-$0.19N/AN/A5/5/2025Q1 2025SNDXSyndax Pharmaceuticals-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFDMT4D Molecular TherapeuticsN/A12.3612.36GHRSGH ResearchN/A29.7129.71IMNMImmunomeN/A10.4910.49SNDXSyndax Pharmaceuticals1.535.805.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFDMT4D Molecular Therapeutics99.27%GHRSGH Research56.90%IMNMImmunome44.58%SNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipFDMT4D Molecular Therapeutics9.60%GHRSGH ResearchN/AIMNMImmunome8.60%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFDMT4D Molecular Therapeutics12046.33 million41.88 millionOptionableGHRSGH Research1052.03 millionN/AOptionableIMNMImmunome4087.01 million79.53 millionOptionableSNDXSyndax Pharmaceuticals11086.05 million82.52 millionOptionableFDMT, GHRS, SNDX, and IMNM HeadlinesRecent News About These CompaniesSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by AnalystsJuly 16 at 2:04 AM | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 6% on Analyst DowngradeJuly 15 at 2:45 PM | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Price Target Cut to $35.00 by Analysts at UBS GroupJuly 15 at 11:19 AM | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Coverage Initiated at The Goldman Sachs GroupJuly 13 at 2:27 AM | americanbankingnews.com3 ‘Strong Buy’ Russell 2000 Stocks with Triple-Digit Upside PotentialJuly 12, 2025 | msn.comThe Goldman Sachs Group Initiates Coverage on Syndax Pharmaceuticals (NASDAQ:SNDX)July 10, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 6.7% - Time to Buy?July 9, 2025 | marketbeat.comSyndax’s Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AMLJuly 9, 2025 | msn.comSyndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug ApprovalsJuly 8, 2025 | seekingalpha.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 (c) (4) - MorningstarJuly 3, 2025 | morningstar.comMSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)July 2, 2025 | globenewswire.comSyndax Pharmaceuticals, Inc. (SNDX) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comSNDX Syndax Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comSyndax Pharmaceuticals Inc News (SNDX) - Investing.comJune 26, 2025 | investing.comSyndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia - MorningstarJune 25, 2025 | morningstar.comMSyndax Gets Priority Review for Leukemia Drug ApplicationJune 24, 2025 | marketwatch.comSyndax stock rises after FDA grants Priority Review for cancer drug expansionJune 24, 2025 | investing.comSyndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML TrialJune 24, 2025 | msn.comSyndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid LeukemiaJune 24, 2025 | globenewswire.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 21, 2025 | marketbeat.comSyndax reports publication of revumenib data from BEAT AML trialJune 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFDMT, GHRS, SNDX, and IMNM Company Descriptions4D Molecular Therapeutics NASDAQ:FDMT$4.29 +0.13 (+3.17%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.GH Research NASDAQ:GHRS$16.43 +0.44 (+2.75%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Immunome NASDAQ:IMNM$9.13 +0.73 (+8.69%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Syndax Pharmaceuticals NASDAQ:SNDX$9.34 +0.13 (+1.41%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
